Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGS67E in Refractory or Relapsed Lymphoid Malignancies
NCT02175433Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2014
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of AGS67E in chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HCL) and 1 more (11 arms), sponsored by Astellas Pharma. Primary endpoints: Incidence and nature of adverse events up to 34 months, Concentration at the end of infusion and 6 more. Started Oct 2014; status: completed.
02
Drugs
AGS67E
03
Conditions
chronic lymphocytic leukemia (CLL)prolymphocytic leukemia (PLL)hairy cell leukemia (HCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02175433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02175433.